Signal

Compact type II-C Cas9 nucleases with expanded PAM access and high fidelity for therapeutic genome editing

Evidence first: scan the strongest sources, then decide whether to go deeper.

Published 2026-08-17 22:28 UTCUpdated 2026-08-18 16:08 UTC
rss
virus
Trend in the last 24h
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (1 domains)domains are deduped. counts indicate coverage, not truth.
1 top source shown
limited source diversity in top sources
Overview

Compact CRISPR nucleases are attractive for therapeutic genome editing because their small coding sequences facilitate delivery by adeno-associated virus.

Score total
1.02
Momentum 24h
3
Posts
3
Origins
1
Source types
1
Duplicate ratio
0%
All evidence
All evidence
Show filters & breakdown
Posts loaded: 0Publishers: 1Origin domains: 1Duplicates: -
Showing 1 / 0
Top publishers (this list)
  • bioRxiv (all subjects) (1)
Top origin domains (this list)
  • biorxiv.org (1)